JHOP - Supplements

There have been significant improvements in the survival of patients with metastatic colorectal cancer (mCRC) over the past decade. However, patients with the disease who fail to respond to first- or second-line therapies, including chemotherapy and monoclonal antibodies, have few treatment options. Advances in subsequent treatment lines rather than in first- or second-line therapies now drive improvements in survival for these patients.

Ovarian cancer is the most lethal gynecologic cancer and the fifth leading cause of cancer death among women in the United States.¹ No effective screening tests are available, and more than 70% of patients are diagnosed with advanced-stage disease.²

Based on current incidence rates, 12.4% of women born in the United States today will develop breast cancer at some time during their life.¹ At the time of diagnosis, breast cancer is generally considered local, but eventually approximately 20% of patients will experience either locoregional or distant disease recurrence.²

Approximately 75% of breast cancers rely on ER signaling to grow and survive.² Endocrine therapy, which blocks the growth-promoting activity of estrogen, represents the primary intervention for early- and advanced-stage ER-positive breast cancer.³ However, some patients do not respond to endocrine therapy (ie, de novo resistance), and some patients who initially respond to therapy have disease that progresses during therapy (ie, acquired resistance).³